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Abstract 
 
Despite advancements in many areas of human medicine, infectious disease continues to 
be a leading cause of morbidity and mortality worldwide.  Improper and excessive use of 
antibacterial compounds has led to the rise of resistant species of bacteria like Methicillin 
Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococci (VRE), and Extreme 
Drug Resistant Tuberculosis (XDR-TB).   We have found a possible alternative that would replace 
the current ineffective treatment methods – a potentially new class of antibiotics that inhibits 
Gram-positive bacteria growth.  These chemical compounds have shown inhibition against S. 
aureus and E. faecalis, so MRSA and VRE strains were then tested.  Inhibition by the newly 
developed compounds was identical to their inhibition levels against non-resistant strains of both 
species.  These carboxylic amide compounds are novel, non-Penicillin based antibiotics, and could 
be used to treat MRSA and other Gram-positive infections. 
 
 
 
 
 
 
 
 
Introduction 
 
Progress in the development of new antibiotics is tapering off, mostly because of recent 
abandonment of natural products and infectious disease discovery programs by several large 
pharmaceutical companies (Baltz, 2007).  This declining interest comes at an inopportune time; 
the rate of infections caused by bacteria that have acquired antibiotic resistance is higher than 
ever.  Strains like Methicillin Resistant Staphylococcus aureus (MRSA) and Vancomycin Resistant 
Enterococci (VRE), are commonly acquired through a nosocomial infection.  Bacteria acquire 
resistance to antibiotics in a variety of ways, one of which is by transferring resistance genes from 
one species of bacterium to another (Barlow, 2009).  Novel antibiotics help prevent resistance 
development in bacteria that stems from natural or synthetically derived sources. Most antibiotics 
currently being utilized in human medicine are direct natural products or semi-synthetic 
derivatives of the soil bacteria Actinomycetes (Baltz, 2007).  Many studies searching for novel 
compounds with antibiotic properties are underway, and the process continues to be at the 
forefront of medical interest (Matijevic-Sosa, 2005). 
  
Our approach to this problem was to synthesize novel compounds and test them for any 
potential inhibitory effect against Gram-positive and Gram-negative bacteria.  The compounds 
tested were derivatives of a known telomerase inhibitor, GV-1, the structure of which is shown in 
Figure 1.  To date, there are no published studies of the effects of GV-1 against bacteria.  Disk 
Diffusion tests, along with tests for Minimum Inhibitory Concentration (MIC’s) where applicable, 
were performed with each compound against Staphylococcus aureus and Escherichia coli.  If a 
compound demonstrated high effectiveness during initial phases of testing, it was also subject to 
further testing for effectiveness against bacteria while in the presence of human serum.  
Methods 
GV-1 and any derivatives (Figure 1) were dissolved in 20%TEA at concentrations ranging 
from 1.25 mg/ml to 10 mg/ml.   Two methods were used to test the possible inhibition of the 
organisms by the compounds: the disk diffusion test, and the test for the minimum inhibitory 
concentration (MIC).  For the disk diffusion tests, 10ul of the compound was placed on sterile 
paper disks.  The disks were placed on top of “lawns” of overnight cultures of organisms and 
allowed to grow for 18-24 hours.  The disk diffusion method was used as the initial screen to 
determine if any inhibition, signified by a zone of clearing (Figure 2), was provided by the 
compound. If inhibition was present, then an MIC test was performed. 
 
 
 
 
 
 
 
GV-1 
(E)-2-(3-(naphthalene-2-yl)but-2-enamido)benzoic acid 
 
 
 
 
 
 
 
 
 
Primary Structure Showing Areas Varied to Synthesize GV-1 Derivatives 
 
 
Figure 1.  Chemical Structure of GV-1 and a primary structure showing areas modified during 
derivative synthesis. 
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Figure 2.  This figure depicts the initial six microorganisms that were sensitive to GV-1 in 
previous tests.  Zones of clearing around the discs are indicative of compound effectiveness.  
Disk Diffusion Test of GV-1 against B. subtilis (A), M. leuteus (B), S. aureus (C), M. smegmatis (D), 
S. epidermidis (E), and S. pneumoniae (F). Disk 1 is a negative control of 20% triethanolamine; 
disk 7 is a positive control of 1mg/ml Ampicillin. Disks 2-6 have the following concentrations of 
GV-1, respectively: 10, 7.5, 5, 2.5, and 1mg/ml. 
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Results 
 
We tested over 25 derivatives of the primary GV-1 compound over the course of the 
summer (see Table 1).  Eight of the compounds tested showed high levels of potency against S. 
aureus.  Of those eight that were highly effective, two compounds were effective enough to 
warrant further testing with human serum.  Those test results showed that the serum bound to 
both compounds, lowering their activity levels significantly. 
 
Table 1. Zone of Inhibition (diameter) and MIC values against S. aureus for GV-1 and synthesized 
derivatives are shown.  
 
Chemical 
Name 
GV-1 WS 
8.72 
WS 
9.57 
WS 
10.2 
WS 
10.14 
WS 
10.18 
Acid 
WS 
10.26 
Acid 
WS 
10.27 
WS 
10.31 
Zone of 
Inhibition 
(mm) 
28 11 20 10 11 21 10 7.5 8 
MIC (ug/ml) 64 256 4 >256 256 8 64 >512 512 
MIC (ug/ml) 
With 10% 
Human Serum 
>256 Not 
Tested 
64 Not 
Tested 
Not 
Tested 
32 Not 
Tested 
Not 
Tested 
Not 
Tested 
 
 
 
 
 
 
 
 
 
 
 
Conclusions 
 
Past research done on the primary GV-1 compound previously showed that it was effective 
against eight Gram-positive and one acid fast species of microorganisms.  This previous work also 
showed that the MICs for the main GV-1 compound and derivatives were equally effective against 
normal and resistant strains of bacteria.  In this study we tested over 25 compounds that were 
novel derivatives of the primary GV-1 compound, and several compounds showed promising 
activity levels with MIC values of 4 or 8.  Although some of the derivatives of GV-1 that we tested 
exhibited increased activity levels when compared to the primary compound, these activity levels 
decreased significantly when human serum was included in the testing.  Our ultimate goal is that 
these antimicrobials could be developed further and eventually used to treat MRSA and other 
Gram-positive infections. 
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